Research & Literature

Interventions in progressive supranuclear palsy.

Koros C, Stamelou M

Parkinsonism & related disorders 2016; (22 Suppl 1()):S93-5.

Tremor in progressive supranuclear palsy.

Fujioka S, Algom AA, Murray ME, et al.

Parkinsonism & related disorders 2016; (27()):93-7.

Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy.

Owens E, Krecke K, Ahlskog JE, et al.

Parkinsonism & related disorders 2016; (28()):107-11.

Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.

Zanigni S, Calandra-Buonaura G, Manners DN, et al.

NeuroImage. Clinical 2016; (11()):736-742 doi:10.1016/j.nicl.2016.05.016.

The clinical spectrum and natural history of pure akinesia with gait freezing.

Owens E, Josephs KA, Savica R, et al.

Journal of neurology 2016; (263(12)):2419-2423 doi:10.1007/s00415-016-8278-x.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, et al.

Movement disorders : official journal of the Movement Disorder Society 2017; (32(6)):853-864 doi:10.1002/mds.26987.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, et al.

Movement disorders : official journal of the Movement Disorder Society 2017; (32(7)):995-1005 doi:10.1002/mds.27034.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, et al.

The Lancet. Neurology 2017; (16(7)):552-563 doi:10.1016/S1474-4422(17)30157-6.

Brain gray matter abnormalities in progressive supranuclear palsy revisited.

Pan P, Liu Y, Zhang Y, et al.

Oncotarget 2017; (8(46)):80941-80955 doi:10.18632/oncotarget.20895.

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Ali F, Martin PR, Botha H, et al.

Movement disorders : official journal of the Movement Disorder Society 2019; (34(8)):1144-1153 doi:10.1002/mds.27619.

Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.

Quattrone A, Morelli M, Vescio B, et al.

Movement disorders : official journal of the Movement Disorder Society 2019; (34(4)):487-495 doi:10.1002/mds.27621.

An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.

Whitwell JL, Stevens CA, Duffy JR, et al.

Movement disorders clinical practice 2019; (6(6)):452-461 doi:10.1002/mdc3.12796.

Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.

Pyatigorskaya N, Yahia-Cherif L, Gaurav R, et al.

Movement disorders : official journal of the Movement Disorder Society 2020; (35(1)):161-170 doi:10.1002/mds.27877.

Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.

Jabbari E, Holland N, Chelban V, et al.

JAMA neurology 2020; (77(3)):377-387 doi:10.1001/jamaneurol.2019.4347.

Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules.

Ogawa T, Hatano T, Oyama G, et al.

Movement disorders clinical practice 2020; (7(2)):240-242 doi:10.1002/mdc3.12894.

Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.

VandeVrede L, Dale ML, Fields S, et al.

Movement disorders clinical practice 2020; (7(4)):440-447 doi:10.1002/mdc3.12940.

Clinical Conditions "Suggestive of Progressive Supranuclear Palsy"-Diagnostic Performance.

Grimm MJ, Respondek G, Stamelou M, et al.

Movement disorders : official journal of the Movement Disorder Society 2020; (35(12)):2301-2313 doi:10.1002/mds.28263.

Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy.

Iankova V, Respondek G, Saranza G, et al.

Parkinsonism & related disorders 2020; (78()):200-203 doi:10.1016/j.parkreldis.2020.06.030.

Reply to: "Brief Clinical Rating Scales Should Not Be Overlooked".

Respondek G, Piot I, Höglinger GU

Movement disorders : official journal of the Movement Disorder Society 2020; (35(10)):1886 doi:10.1002/mds.28273.

Gait initiation in progressive supranuclear palsy: brain metabolic correlates.

Palmisano C, Todisco M, Marotta G, et al.

NeuroImage. Clinical 2020; (28()):102408 doi:10.1016/j.nicl.2020.102408.

A Modified Progressive Supranuclear Palsy Rating Scale.

Grötsch MT, Respondek G, Colosimo C, et al.

Movement disorders : official journal of the Movement Disorder Society 2021; (36(5)):1203-1215 doi:10.1002/mds.28470.

Association of PSP phenotypes with survival: A brain-bank study.

Guasp M, Molina-Porcel L, Painous C, et al.

Parkinsonism & related disorders 2021; (84()):77-81 doi:10.1016/j.parkreldis.2021.01.015.

Subtypes of PSP and Prognosis: A Retrospective Analysis.

Mahale RR, Krishnan S, Divya KP, et al.

Annals of Indian Academy of Neurology 2021; (24(1)):56-62 doi:10.4103/aian.AIAN_611_20.

Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy.

Clark HM, Tosakulwong N, Weigand SD, et al.

Movement disorders : official journal of the Movement Disorder Society 2021; (36(11)):2669-2675 doi:10.1002/mds.28731.

Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus.

Virhammar J, Blohmé H, Nyholm D, et al.

Journal of neuroimaging : official journal of the American Society of Neuroimaging 2022; (32(1)):90-96 doi:10.1111/jon.12932.

"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

Necpál J, Borsek M, Jeleňová B

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):4927-4936 doi:10.1007/s10072-021-05601-8.

Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.

Street D, Malpetti M, Rittman T, et al.

Brain communications 2021; (3(3)):fcab206 doi:10.1093/braincomms/fcab206.

Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy.

Kok ZQ, Murley AG, Rittman T, et al.

Movement disorders clinical practice 2021; (8(8)):1225-1233 doi:10.1002/mdc3.13339.

Accuracy of Magnetic Resonance Parkinsonism Index in Differentiating Progressive Supranuclear Palsy from Parkinson's Disease among South Indian Population: A Retrospective Case Control Study.

Janarthanan V, Nadhamuni K, Rajakumar S, et al.

The Indian journal of radiology & imaging 2021; (31(3)):596-600 doi:10.1055/s-0041-1736402.

Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.

Grijalva RM, Pham NTT, Huang Q, et al.

Movement disorders : official journal of the Movement Disorder Society 2022; (37(4)):702-712 doi:10.1002/mds.28901.

Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.

Bower SM, Weigand SD, Ali F, et al.

Movement disorders clinical practice 2022; (9(2)):212-217 doi:10.1002/mdc3.13396.

Protracted course progressive supranuclear palsy.

Couto B, Martinez-Valbuena I, Lee S, et al.

European journal of neurology 2022; (29(8)):2220-2231 doi:10.1111/ene.15346.

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.

Quattrone A, Bianco MG, Antonini A, et al.

Movement disorders : official journal of the Movement Disorder Society 2022; (37(6)):1272-1281 doi:10.1002/mds.28992.

Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review.

Macedo AC, Mariano LI, Martins MI, et al.

Movement disorders clinical practice 2022; (9(4)):436-445 doi:10.1002/mdc3.13435.

Real-life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1-year follow-up data report.

Metta V, Chaudhuri KR, Leta V, et al.

Brain and behavior 2022; (12(9)):e2547 doi:10.1002/brb3.2547.

Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel.

Barer Y, Chodick G, Cohen R, et al.

Brain sciences 2022; (12(9)) doi:10.3390/brainsci12091126.

Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings.

Mena AM, Chen R, Graff-Guerrero A, et al.

Movement disorders clinical practice 2023; (10(12)):1725-1737 doi:10.1002/mdc3.13885.

Physiotherapy case reports on three people with progressive supranuclear palsy.

Mateus M, Castro Caldas A

Frontiers in aging neuroscience 2023; (15()):1294293 doi:10.3389/fnagi.2023.1294293.

Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome.

Parmera JB, de Godoi Carneiro C, de Almeida IJ, et al.

Movement disorders clinical practice 2024; (11(3)):238-247 doi:10.1002/mdc3.13959.

Predicting Disability in Progressive Supranuclear Palsy Using Bedside Frontal-Lobe Signs.

Ruiz-Barrio I, Horta-Barba A, Aracil-Bolaños I, et al.

Movement disorders clinical practice 2024; (11(3)):248-256 doi:10.1002/mdc3.13958.

The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.

Buchholz S, Zempel H

Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; (20(5)):3606-3628 doi:10.1002/alz.13784.

Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants.

Black JA, Pham NTT, Ali F, et al.

Journal of neurology 2024; (271(7)):4267-4280 doi:10.1007/s00415-024-12350-z.

Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.

Orlandi F, Carlos AF, Ali F, et al.

Brain communications 2024; (6(2)):fcae113 doi:10.1093/braincomms/fcae113.

Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies.

DeRosier F, Hibbs C, Alessi K, et al.

Disease-a-month : DM 2024; (70(8)):101753 doi:10.1016/j.disamonth.2024.101753.

Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life.

Fabbri M, Ledda C, Schirinzi T, et al.

Parkinsonism & related disorders 2024; (125()):107047 doi:10.1016/j.parkreldis.2024.107047.

MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.

Ressler HW, Humphrey J, Vialle RA, et al.

Acta neuropathologica communications 2024; (12(1)):135 doi:10.1186/s40478-024-01839-3.

An autopsy case of progressive supranuclear palsy with severe corticospinal tract degeneration.

Kuru S, Sakai M, Moriyoshi H, et al.

Neuropathology : official journal of the Japanese Society of Neuropathology 2024; (44(6)):452-458 doi:10.1111/neup.13001.

Dysphagia in progressive supranuclear palsy: A scoping review.

Flynn É, Regan J, Glinzer J, et al.

Clinical parkinsonism & related disorders 2024; (11()):100283 doi:10.1016/j.prdoa.2024.100283.

A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.

Dam T, Yang L, Gillis C, et al.

Nature communications 2025; (16(1)):414 doi:10.1038/s41467-024-55442-0.

Overlap in the diagnostic criteria of frontotemporal dementia syndromes with parkinsonism.

Heikkinen S, Katisko K, Haapasalo A, et al.

Journal of Alzheimer's disease : JAD 2025; (104(2)):374-381 doi:10.1177/13872877251316804.

Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.

Marchand F, Blaise AS, Defebvre L, et al.

Journal of Parkinson's disease 2024; (14(8)):1652-1658 doi:10.1177/1877718X241291996.

Brainstem and cerebellar radiological findings in progressive supranuclear palsy.

Spiegel C, Marotta C, Bertram K, et al.

Brain communications 2025; (7(1)):fcaf051 doi:10.1093/braincomms/fcaf051.

Head position control strategies in progressive Supranuclear Palsy versus Idiopathic Parkinson's Disease during dynamic-on-static platform tilt.

Kammermeier S, Maierbeck K, Dietrich L, et al.

Frontiers in neurology 2024; (15()):1477493 doi:10.3389/fneur.2024.1477493.

The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.

Morales-Rivero A, Garcia-Cordero I, Khoja A, et al.

European journal of neurology 2025; (32(6)):e70248 doi:10.1111/ene.70248.

Motor and non-motor features in progressive supranuclear palsy: the impact of microtubule associated protein tau haplotypes among a Tunisian cohort.

Abida Y, Sghaier I, Souissi A, et al.

Journal of neural transmission (Vienna, Austria : 1996) 2026; (133(3)):423-432 doi:10.1007/s00702-025-03004-z.

Progressive Supranuclear Palsy-A Global Review.

Kukkle PL, Neupane R, Pantelyat A, et al.

Movement disorders clinical practice 2026; (13(3)):611-622 doi:10.1002/mdc3.70338.

Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

Ono D, Sekiya H, Ghayal NB, et al.

Journal of neurology 2025; (272(10)):704 doi:10.1007/s00415-025-13459-5.

Tau-Mitochondria Interactions in Neurodegeneration: Mechanisms and Therapeutic Potential.

Castillo-Casaña Y, Arias C, Coria R

Cellular and molecular neurobiology 2025; (46(1)):3 doi:10.1007/s10571-025-01634-1.

18 F-FDG, 18 F-FP-CIT, and 18 F-Florzolotau PET Imaging in Progressive Supranuclear Palsy : Region-Specific Correlations Between Glucose Metabolism, Dopaminergic Function, and Tau Pathology.

Liang M, Jia C, Huang Z, et al.

Clinical nuclear medicine 2026; (51(3)):220-225 doi:10.1097/RLU.0000000000006254.

4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy.

Martinez-Valbuena I, Lee S, Santamaria E, et al.

Nature communications 2025; (17(1)):1006 doi:10.1038/s41467-025-67744-y.